CompanyGraph
The Cigna Group
CI · NYSE Arca · United States
Captures both the formulary management fee and the dispensing margin on a single prescription by routing plan-administered drug volume through owned Express Scripts mail-order and specialty pharmacy infrastructure.
Evernorth's dual-capture mechanism works because its administrative role in formulary management directs prescription volume toward owned Express Scripts facilities, generating both a PBM contract payment and a dispensing take on the same transaction. That mechanism can only activate in markets where state insurance departments have already certified the arm's-length transfer-pricing documentation separating formulary decisions from pharmacy economics, making regulatory approval the rate-limiting step for geographic expansion rather than operational capacity. Each additional covered life scales the contract-payment-and-dispensing-take pair without proportional overhead, but only within already-certified states, so the business grows unevenly — deepening returns in established markets faster than it can replicate the compliance infrastructure required to enter new ones. Federal scrutiny of vertical PBM-pharmacy integration threatens to sever the link between formulary position and dispensing volume entirely, which would dissolve the dual-capture structure into two ordinary single-take businesses, though employer switching cycles of 12–18 months and the complexity of transferring specialty pharmacy patients create friction that slows any forced structural change.
How does this company make money?
Money enters through premiums on medical coverage, PBM administrative fees and pharmaceutical manufacturer rebates through Evernorth operations, dispensing amounts collected by Express Scripts mail-order and specialty pharmacy facilities, and international premiums denominated in local currencies across Asian and European markets.
What makes this company hard to replace?
Employer clients face 12–18 month implementation cycles to separate integrated medical-pharmacy benefits across different vendors. Evernorth specialty pharmacy patients require complex prior authorization transfers and physician coordination to move high-cost therapies to a new PBM network. Express Scripts mail-order patients experience prescription transfer delays that require temporary retail fills in the interim.
What limits this company?
State insurance department approval of medical loss ratio calculations — each requiring documentation that PBM rebates and pharmacy income flowing within the same corporate structure reflect arm's-length transfer pricing — is the rate-limiting step for geographic expansion. The dual-margin mechanism cannot legally operate in a new market until the relevant regulator has certified that actuarial separation.
What does this company depend on?
Evernorth depends on Express Scripts mail-order pharmacy facilities for prescription fulfillment, pharmaceutical manufacturer rebate contracts negotiated through its PBM operations, state insurance licenses across all markets where Cigna Healthcare operates, claims processing systems that interface with Evernorth pharmacy networks, and Medicare Advantage and Medicaid managed care contracts in specific state markets.
Who depends on this company?
Employer groups purchasing integrated medical-pharmacy benefits would face plan redesign costs and employee disruption if forced to split PBM and medical coverage across different vendors. Express Scripts mail-order patients with chronic conditions would experience therapy interruptions requiring physician intervention to transfer their prescriptions. Specialty pharmacy patients receiving high-cost biologics through Evernorth would face prior authorization delays with new PBMs unfamiliar with their treatment histories.
How does this company scale?
PBM rebate negotiations and pharmacy network contracts replicate across additional covered lives without proportional increases in administrative overhead. State-by-state insurance regulatory relationships and medical provider network construction in new geographic markets, however, require local expertise and compliance infrastructure that cannot be centralized or automated, and remain the bottleneck as the business grows.
What external forces can significantly affect this company?
Federal Trade Commission scrutiny of vertical integration between PBMs and pharmacies carries the potential to force structural separation. Medicare Advantage benchmark rate adjustments by CMS affect the economics of government program participation. International currency fluctuations affect health coverage sold in Asian and European markets, where premiums are denominated in local currencies.
Where is this company structurally vulnerable?
If the FTC or state regulators successfully challenge the arm's-length characterization of intra-company PBM-to-pharmacy volume direction and compel divestiture of either the pharmacy operations or the PBM business, the link between formulary position and dispensing margin is severed. The dual-capture mechanism dissolves into two ordinary single-margin businesses, neither of which retains the differentiator.